CHAIR
:
SPEAKER
(S):
Dr. Sudhir Agrawal, MSc, D Phil, Chief Executive Officer and Chief Scientific Officer, Idera Pharmaceuticals, Inc.
Dr. Arthur Krieg, MD, Chief Scientific Officer, Coley Pharmaceutical Group
Robert Coffman, PhD, Vice President and Chief Scientific Officer, Dynavax Technologies
Description
The ability of Toll-like receptors (TLRs) to regulate diverse cytokine responses has generated great interest in TLRs as drug development targets for a broad range of diseases including cancer, infections, asthma/allergies and autoimmune problems. The experts on this panel will present a variety of drug discovery approaches to create agonists and antagonists to different TLRs and clinical development progress toward realizing the full therapeutic potential of TLR modulators.
Objectives:
Describe Toll-like receptors that are targets of drug discovery and development programs.
Understand medicinal chemistry approaches to the creation of agonists and antagonists to Toll-like receptors.
Discuss progress of clinical development programs based on Toll-like receptor modulators in diverse therapeutic areas.